Kura Oncology Conference Call Summary Company Overview - **Company**: Kura Oncology (NasdaqGS: KURA) - **Event**: Discussion of FTI clinical data at the ESMO 2025 Congress - **Date**: October 18, 2025 Key Points Industry and Product Focus - **Focus**: Farnesyltransferase inhibitors (FTIs), specifically KO-2806 (DARLI/Farnib) - **Target Indications**: Advanced HRAS-mutant solid tumors, renal cell carcinoma (RCC), and PIK3CA-mutant head and neck cancers [2][3][4] Clinical Data Highlights 1. **KO-2806 Monotherapy in HRAS-Mutant Tumors** - KO-2806 demonstrated encouraging safety and tolerability with manageable adverse events (AEs) such as neutropenia and anemia [11][12] - Monotherapy activity showed stable disease and partial responses in various tumor types, with a notable response rate at lower doses (5-8 mg) [14][16] - Patients exhibited durable responses, with some remaining on treatment for over 20 months [14][15] 2. **Combination Data with Cabozantinib in RCC** - KO-2806 combined with Cabozantinib showed a response rate of 33% to 50% in clear cell RCC patients, with a disease control rate of 80% to 100% [26][27] - The combination was well tolerated, with no significant overlapping toxicities observed [21][22] - Encouraging activity was noted even in patients previously treated with Cabozantinib, indicating potential for resensitization [26][27] 3. **Combination with PI3K Inhibitors in Head and Neck Cancer** - A phase I study combining Tipifarnib (another FTI) with alpelisib showed a nearly 50% response rate in patients with PIK3CA alterations [32][33] - The combination demonstrated robust antitumor activity and manageable safety profiles, addressing adaptive resistance mechanisms [37] Future Development Plans - Kura Oncology plans to complete dose escalation studies for KO-2806 in combination with Cabozantinib and Adagrasib in KRAS G12C-mutant patients [39][40] - The company aims to explore further combinations with PI3K inhibitors and share additional data in the coming year [39][40] Market Potential - The total addressable market for KO-2806 and FTIs is estimated to exceed 200,000 patients across various indications, highlighting significant growth opportunities [41] Additional Insights - The conference emphasized the importance of combining FTIs with targeted therapies to enhance patient outcomes and address challenges in current treatment paradigms [41][42] - The safety profile of KO-2806 is considered a key advantage, allowing for potential combinations with other therapies without significant dose-limiting toxicities [12][21] Conclusion Kura Oncology's ongoing clinical trials and data presentations at ESMO 2025 indicate promising developments in the use of KO-2806 and FTIs in treating various cancers, particularly in combination therapies that enhance efficacy while maintaining safety. The company is positioned to explore further opportunities in the oncology market, leveraging its innovative drug development strategies.